A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy

BACKGROUND: To compare the safety and efficacy of saxagliptin 2.5 mg twice daily (BID) versus placebo add-on therapy to metformin immediate release (IR) in patients with type 2 diabetes and inadequate glycemic control with metformin alone. METHODS: This multicenter, 12-week, double-blind, parallel-g...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Judith L, Buchanan, Patricia, Li, Jia, Frederich, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946011/
https://www.ncbi.nlm.nih.gov/pubmed/24565221
http://dx.doi.org/10.1186/1472-6823-14-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946011/
https://www.ncbi.nlm.nih.gov/pubmed/24565221
http://dx.doi.org/10.1186/1472-6823-14-17

Ejemplares similares